drugset / Trial / NCT01166243

The Fibrin Pad Liver Study

NCT01166243 ↗

Phase 3 Completed 84 enrolled Ethicon, Inc. OMRIX Biopharmaceuticals · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The objective of this study is to evaluate the safety and and hemostatic effectiveness of the Fibrin Pad (FP) versus standard of care treatment (SoC) in controlling parenchymal bleeding during hepatic surgery.

Timeline

Start
2010-07
Primary completion
2011-08
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Fibrin Pad Other / unclassified — Topical

Indications